Qingdao Vland Biotech INC. (SHA:603739)
China · Delayed Price · Currency is CNY 12.93
-0.17 (-1.30%)
Sep 2, 2026, 2:09 PM CST
SHA:603739 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,315 | 3,580 | 3,034 | 3,851 | 3,387 | 4,689 | |
Market Cap Growth | -10.52% | 18.02% | -21.22% | 13.69% | -27.76% | 34.98% |
Enterprise Value | 3,624 | 3,953 | 3,413 | 4,153 | 3,512 | 4,417 |
Last Close Price | 13.10 | 14.04 | 11.81 | 14.89 | 13.03 | 17.87 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 41.14 | 51.29 | 48.44 | 47.72 | 48.50 | 35.37 |
Forward PE | 37.43 | 39.58 | 30.10 | 29.41 | 29.50 | 20.11 |
PS Ratio | 2.33 | 2.62 | 2.30 | 3.21 | 2.91 | 4.07 |
PB Ratio | 1.74 | 1.87 | 1.62 | 2.11 | 1.95 | 2.78 |
P/TBV Ratio | 2.11 | 2.28 | 1.99 | 2.59 | 2.28 | 3.23 |
P/FCF Ratio | 35.60 | 105.50 | 33.45 | - | - | - |
P/OCF Ratio | 20.70 | 31.42 | 15.53 | 25.07 | 35.54 | 52.38 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.55 | 2.89 | 2.58 | 3.46 | 3.02 | 3.84 |
EV/EBITDA Ratio | 15.96 | 19.53 | 15.14 | 23.48 | 24.16 | 24.35 |
EV/EBIT Ratio | 32.65 | 45.73 | 29.83 | 40.27 | 44.08 | 34.05 |
EV/FCF Ratio | 38.93 | 116.49 | 37.64 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.35 | 0.36 | 0.34 | 0.40 | 0.30 | 0.14 |
Debt / EBITDA Ratio | 2.95 | 3.35 | 2.82 | 4.09 | 3.60 | 1.30 |
Debt / FCF Ratio | 7.18 | 20.00 | 7.01 | - | - | - |
Net Debt / Equity Ratio | 0.10 | 0.11 | 0.10 | 0.11 | 0.06 | -0.15 |
Net Debt / EBITDA Ratio | 0.87 | 1.04 | 0.83 | 1.09 | 0.67 | -1.36 |
Net Debt / FCF Ratio | 2.11 | 6.18 | 2.07 | -3.10 | -0.39 | 0.61 |
Asset Turnover | 0.48 | 0.45 | 0.44 | 0.43 | 0.49 | 0.63 |
Inventory Turnover | 3.44 | 3.66 | 3.69 | 3.42 | 4.01 | 4.40 |
Quick Ratio | 0.96 | 0.91 | 0.83 | 0.82 | 1.19 | 2.08 |
Current Ratio | 1.24 | 1.17 | 1.04 | 1.03 | 1.50 | 2.61 |
Return on Equity (ROE) | 5.89% | 5.16% | 4.99% | 5.78% | 5.00% | 10.72% |
Return on Assets (ROA) | 2.33% | 1.80% | 2.38% | 2.30% | 2.08% | 4.42% |
Return on Invested Capital (ROIC) | 4.18% | 3.26% | 4.19% | 4.50% | 4.07% | 9.99% |
Return on Capital Employed (ROCE) | 5.50% | 4.30% | 5.90% | 5.30% | 4.10% | 7.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.46% | 1.95% | 2.07% | 2.10% | 2.06% | 2.83% |
FCF Yield | 2.81% | 0.95% | 2.99% | -1.61% | -7.28% | -8.62% |
Dividend Yield | 0.80% | 0.71% | 0.85% | 0.67% | 0.77% | 0.90% |
Payout Ratio | 51.04% | 61.61% | 88.18% | 49.28% | 75.55% | 28.50% |
Buyback Yield / Dilution | -2.69% | 0.49% | 0.66% | 2.50% | -5.36% | -8.14% |
Total Shareholder Return | -1.89% | 1.20% | 1.50% | 3.17% | -4.60% | -7.24% |